Insight Molecular Diagnostics (IMDX) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Insight Molecular Diagnostics is the larger company by market cap ($105.4 million vs $2.6 million), about 40.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | IMDX | VRAX |
|---|---|---|
| Share price | $3.22 | $1.95 |
| Market cap | $105.37M | $2.62M |
| 1-day change | -6.95% | -7.58% |
| YTD return | -53.87% | — |
| 1-year return | -5.98% | — |
| 5-year return | -94.91% | — |
| EPS (TTM) | $-1.52 | $-12.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.51 | $21.75 |
| 52-week low | $2.42 | $1.83 |
| Distance from 52-week high | -62.16% | -91.03% |
| Average volume | 233.13K | 1.77M |
| Shares outstanding | 32.72M | 1.34M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Insight Molecular Diagnostics is about 40.2 times larger than Virax Biolabs Group by market value ($105.37M vs $2.62M).
IMDX vs VRAX FAQ
Which is bigger, Insight Molecular Diagnostics or Virax Biolabs Group?
Insight Molecular Diagnostics (IMDX) is larger, with a market capitalization of $105.37M compared with $2.62M for Virax Biolabs Group (VRAX).
Are Insight Molecular Diagnostics and Virax Biolabs Group in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.